Researchers tracked data from more than 600,000 procedures, noting that 30-day outcomes for operators with less than five years of experience were comparable to those for more experienced specialists.
Researchers found that AI-generated preliminary reports were noninferior to those built by experienced sonographers and cardiologists. It is still true, however, that all final reports need to be reviewed by a trained specialist.
An FDA statement called the new approval of Bayer's asundexian a "meaningful advance for patients and healthcare providers seeking a new option for secondary stroke prevention."
The FDA has categorized this as a Class I recall. However, patients can still use the devices as long as they follow specific instructions provided by the manufacturer.
The greater cardiology community was hopeful ZEUS could open the door for significant improvements in patient care. After the trial failed to deliver on that promise, it's time to consider where things went wrong.
GLP-1 receptor agonists have been associated with a wide range of potential benefits for patients with and without type 2 diabetes. The team behind this new meta-analysis hoped to learn more about how the popular medications may impact a person's risk of new-onset AFib.
A new analysis suggests that these AI-assessed scores could help identify patients at elevated cardiovascular risk even when their coronary calcium levels are low or absent on imaging.
Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.
